About ProtoKinetix

Changing lives through cell survival

Iceberg animation

Based on a molecule found in nature and harnessed by a world-class research team, this anti-aging glycopeptide keeps more cells alive longer. It utilizes the same properties that help animals survive in arctic temperatures, and it has the capability to change regenerative medicine forever.

Molecule float

Our vision

With AAGP®, health therapies will become more effective, more affordable and more accessible. We will get closer to cures for conditions such as Type 1 diabetes, macular degeneration, heart disease and stroke. More lives will improve, and more people will get the treatments they deserve.

Picture of a man

Key Milestones

  • 2002
    Public listing on open market
  • 2005
    Initiation of pre-clinical type 1 diabetes research at the University of Alberta (Dr. James Shapiro)
  • 2006
    Lead Scientist, Dr. Geraldine Deliencourt awarded prestigious Francinov medal for scientific excellence in the field of chemistry forming the basis of AAGP®
  • 2010
    Good Manufacturing Practice processing established and preliminary toxicology assessment successful (with AmbioPharm)
  • 2014
    Patent filing for type 1 diabetes with islet transplantation
  • 2015
    Clarence Smith installed as Chief Executive Officer
  • 2016
    Macular degeneration cell therapy program started at the University of British Columbia
  • 2016
    Patent filing for macular degeneration with induced pluripotent stem cells
  • 2016
    Preclinical validation of AAGP® in type 1 diabetes and peer-reviewed paper 
  • 2016
    Patent expanded for macular degeneration with induced pluripotent stem cells
  • 2016
    Patent filing for macular degeneration with neurosensory precursor cells
  • 2017
    Pre-clinical proof of concept for AAGP® in macular degeneration and peer-reviewed paper
  • 2017
    Acquired approval from Health Canada for Phase-1a clinical trial type 1 diabetes using islet cell grafting (Dr. James Shapiro)
  • 2018
    Enhanced biological production and hematopoietic stem cell recovery research program initiated at the University of British Columbia
  • 2018
    Cardiovascular research program started at Dalhousie University (Dr. Thomas Pulinilkunnil)
  • 2019
    Completed pre-clinical macular degeneration cell graft studies (Dr. Gregory Evans)
  • 2019
    Completed pre-clinical ocular safety study in small animal (EyeCro)
  • 2019
    Completed pre-clinical ocular safety study in large animal (Charles River)
  • 2019
    Completed pre-clinical ocular efficacy study (EyeCro)
  • 2020
    Acquired approval from Health Canada for Phase-1b clinical trial type 1 diabetes using islet cell grafting
  • 2020
    Established partnership with IQVIA to execute go-forward strategy for dry eye disease clinical trial and commercialization program
  • 2020
    Patent filing for AAGP® for use in dry eye disease
  • 2021
    Pre-clinical validation of AAGP® in macular degeneration in peer-reviewed paper
  • 2021
    Completion of eye drop formulation for validation studies
Explore ProtoKinetix

Research pipeline

We are moving cell survival forward by addressing the health conditions that affect our lives. See where we are today and where we are heading next.

Leadership team

The leaders at ProtoKinetix have a clear vision for the future of the company and for the future of regenerative medicine. Learn more about their backgrounds.